Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $49.30 | Total: $246.50 |
| 1 | 10 | $41.76 | Total: $417.60 |
| 1 | 25 | $35.38 | Total: $884.50 |
| 1 | 50 | $30.16 | Total: $1,508.00 |
| 1 | 100 | $26.10 | Total: $2,610.00 |
Overview
Lusutrombopag (Mulpleta) is an orally bioavailable, small molecule thrombopoietin (TPO) receptor agonist for chronic liver disease (CLD) patients with thrombocytopenia prior to elective invasive surgery.
Chemical Properties
| Molecular Formula | C29H32Cl2N2O5S |
| Molecular Weight | 591.55 |
| CAS Numbers | 1110766-97-6 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | CCCCCCO[C@@H](C)c1cccc(-c2csc(NC(=O)c3cc(Cl)c(C=C(C)C(O)=O)c(Cl)c3)n2)c1OC |
Storage and Handling
0C Short Term, -20C Long Term
References
Kim ES, et al. Lusutrombopag First Global Approval. Drugs. 2016 Jan;76[1] 155-8.